News stories about Ionis Pharmaceuticals (NASDAQ:IONS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.0558494974329 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen (finance.yahoo.com)
- Ionis Pharmaceuticals, Inc. (IONS) Director Joseph Klein III Sells 2,250 Shares (americanbankingnews.com)
- Ionis Pharmaceuticals, Inc. (IONS) SVP Elizabeth L. Hougen Sells 7,000 Shares (americanbankingnews.com)
- Ionis Pharma (IONS) Agrees to License Second Orally Delivered … – StreetInsider.com (streetinsider.com)
- Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program In Patients With Rare Hyperlipidemias – Clinical Leader (clinicalleader.com)
Ionis Pharmaceuticals (IONS) opened at $54.15 on Friday. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. Ionis Pharmaceuticals has a one year low of $37.26 and a one year high of $65.51. The stock has a market capitalization of $6,757.70, a price-to-earnings ratio of 361.00 and a beta of 2.90.
A number of equities analysts have commented on the company. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price objective on the stock in a research note on Tuesday, October 17th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Stifel Nicolaus reissued a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $30.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. Finally, Barclays PLC assumed coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $50.31.
TRADEMARK VIOLATION NOTICE: “Ionis Pharmaceuticals (IONS) Given Coverage Optimism Rating of 0.08” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://sportsperspectives.com/2017/11/19/ionis-pharmaceuticals-ions-given-coverage-optimism-rating-of-0-08.html.
In related news, COO B Lynne Parshall sold 16,118 shares of the company’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $65.00, for a total value of $1,047,670.00. Following the completion of the sale, the chief operating officer now owns 33,526 shares in the company, valued at $2,179,190. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Patrick R. O’neil sold 1,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. Following the completion of the sale, the senior vice president now owns 10,633 shares of the company’s stock, valued at approximately $584,815. The disclosure for this sale can be found here. Insiders have sold 110,886 shares of company stock worth $6,391,045 in the last ninety days. 2.13% of the stock is currently owned by insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.